ライフサイエンスコーパス: trabeculectomy

1 on to mitomycin concentration applied during trabeculectomy.

2 , and $29 055 per QALY for tube insertion vs trabeculectomy.

3 on after EX-PRESS implantation compared with trabeculectomy.

4 after treatment with the EX-PRESS device and trabeculectomy.

5 functional improvements may occur following trabeculectomy.

6 to private patients with attending-performed trabeculectomy.

7 eated with EX-PRESS and 61 eyes treated with trabeculectomy.

8 e consecutive visits 3 months or later after trabeculectomy.

9 ents with uncontrolled glaucoma after failed trabeculectomy.

10 ent a successful right Mitomycin C-augmented trabeculectomy.

11 g bleb in patients after previous successful trabeculectomy.

12 dary glaucoma, and 37% had previously failed trabeculectomy.

13 ed as the most frequent late complication of trabeculectomy.

14 necessarily represent clinical failure after trabeculectomy.

15 eyes that have undergone previous successful trabeculectomy.

16 th caution, especially in eyes with previous trabeculectomy.

17 which appears to be comparable with standard trabeculectomy.

18 trabeculectomy has a lower success rate than trabeculectomy.

19 imilar between limbus-based and fornix-based trabeculectomy.

20 surgeons regarding the use of tube shunts or trabeculectomy.

21 rs potentially associated with low IOP after trabeculectomy.

22 less endothelial loss is induced than after trabeculectomy.

23 ess and limiting scar tissue formation after trabeculectomy.

24 low-up in eyes following previous successful trabeculectomy.

25 likely to have had hypotony after study eye trabeculectomy.

26 LO as adjuvant compared to low-dosage MMC in trabeculectomy.

27 nly utilized to enhance the success rates of trabeculectomy.

28 m had failed or were at high risk of failing trabeculectomy.

29 s at the time of their MMC-augmented primary trabeculectomy.

30 as increased the rate of complications after trabeculectomy.

31 s patients who underwent attending-performed trabeculectomies.

32 85 eyes) or combined phacoemulsification and trabeculectomy (10 eyes) and were randomized to MMC or C

33 ab interno trabeculectomy (43.5%) than after trabeculectomy (10.8%, P<0.001).

34 The preceding surgeries were trabeculectomy (11 eyes), cataract surgery (10 eyes), an

35 significantly greater than in patients after trabeculectomy (2/61 [3%]; 95% confidence interval, 0.4-

36 5% CI, $1644-$1770) for medical treatment vs trabeculectomy, $3904 (95% CI, $3858-$3953) for medical

37 After trabeculectomy, 42 out of 57 eyes (73.7%) reached the ta

38 a procedures were performed after ab interno trabeculectomy (43.5%) than after trabeculectomy (10.8%,

39 ion of preoperative IOP were achieved by 337 trabeculectomies (78%) without IOP-lowering treatment an

40 evious incisional glaucoma surgery underwent trabeculectomy (85 eyes) or combined phacoemulsification

41 %) without IOP-lowering treatment and by 367 trabeculectomies (86%) including hypotensive medication.

42 In combined phacoemulsification and trabeculectomy, a one-site approach induces less endothe

43 than in the group of patients who underwent trabeculectomy after 6 months (p = 0.003), 12 months (p

44 Compared to trabeculectomy after PK, trabeculectomy after DSAEK achieved lower mean IOP at 12

45 Twenty patients with trabeculectomy after DSAEK and 41 patients with trabecul

46 Trabeculectomy after failed goniotomy surgery or as a pr

47 Trabeculectomy after phacoemulsification was uncommon; t

48 beculectomy after DSAEK and 41 patients with trabeculectomy after PK were analyzed.

49 Compared to trabeculectomy after PK, trabeculectomy after DSAEK achi

50 o-bypass (TMB) implantation or by ab interno trabeculectomy (AIT).

51 ymptoms from those that underwent fellow eye trabeculectomy (all P > .05).

52 tomy (SCB: 6; C: 3), NPGS (SCB: 3; C: 2) and trabeculectomy alone (SCB: 1; C: 1).

53 his is a promising solution to rescue failed trabeculectomies and can potentially prolong trabeculect

54 EX-PRESS shunt, compared to trabeculectomy and Ahmed valve, seems to be a safer proc

55 =4 reliable VF measurements before and after trabeculectomy and at least 4 years of follow-up before

56 of IOP in the eyes after previous successful trabeculectomy and deterioration of filtering bleb morph

57 The time between trabeculectomy and each outcome was compared between cas

58 mitomycin C-augmented combined trabeculotomy-trabeculectomy and may be recommended as the initial sur

59 The types of GFS included trabeculectomy and non-penetrating glaucoma surgery (NPG

60 In the group of patients subjected to both trabeculectomy and phacoemulsification, mean IOP was sig

61 ected to promote attachment, 1 eye (2%) with trabeculectomy and progressive synechiae demonstrated la

62 ors for low intraocular pressure (IOP) after trabeculectomy and to describe long-term outcomes in the

63 The continued movement away from trabeculectomy and toward alternative intraocular pressu

64 ng a willingness to pay of $50 000 per QALY, trabeculectomy and tube insertion are cost-effective com

65 Trabeculectomy and tube shunt surgery had similar impact

66 Forty-two rabbits underwent trabeculectomy and were randomly assigned to receive a p

67 , or pigmentary glaucoma, who failed a first trabeculectomy and who were >/=40 years of age at the ti

68 of 1959 eyes of 1423 patients who underwent trabeculectomy and who were followed for >/=1 year were

69 ients 18 to 85 years of age who had previous trabeculectomy and/or cataract extraction with intraocul

70 nd the incidence of complications related to trabeculectomy and/or corneal graft surgery.

71 o Cucamonga, CA]), 61 patients had undergone trabeculectomy, and 87 patients were medically treated.

72 n, trabecular micro-bypass stent, ab interno trabeculectomy, and canaloplasty may be performed in con

73 ery was found in similar proportions of GDD, trabeculectomy, and medically treated cases (3/47 [6%],

74 imilar proportion of medically treated, post-trabeculectomy, and post-GDD cases (4/87 [5%], 4/61 [7%]

75 The utility gained after medical treatment, trabeculectomy, and tube insertion was 3.10, 3.30, and 3

76 The mean costs for medical treatment, trabeculectomy, and tube insertion were $6172, $7872 and

77 st-effectiveness ratio of medical treatment, trabeculectomy, and tube insertion.

78 s would be viscocanalostomy, thereby keeping trabeculectomy as an alternative.

79 Proportion of failed trabeculectomies at 24 months, defined as the need for r

80 l study was performed of patients undergoing trabeculectomy at the Stein Eye Institute.

81 tients) underwent resident-performed primary trabeculectomy at the VAH with mean follow-up duration o

82 omy (Group I) or combined trabeculotomy with trabeculectomy augmented with mitomycin C (Group II).

83 Clinical studies comparing trabeculectomy augmented with Ologen implant (OLO) versu

84 sicians ("attendings") who underwent primary trabeculectomy between 2003 and 2012 with >/=6 months of

85 st 12 years of age coded as having undergone trabeculectomy between May 2000 and October 2008 by 1 of

86 my on the intraocular pressure (IOP) and the trabeculectomy bleb integrity, in a small series of eyes

87 n of bevacizumab is associated with improved trabeculectomy bleb survival in the rabbit model.

88 aucoma procedures appear less effective than trabeculectomy, but they are associated with a lower ris

89 Evaluating filtering blebs after trabeculectomy by using the Wuerzburg bleb classificatio

90 Consecutive trabeculectomy cases with open-angle glaucoma and no pre

91 urgery was hypertropia (10/11 GDD cases, 2/2 trabeculectomy cases).

92 hty-five patients were included in the final trabeculectomy cohort after accounting for declining tre

93 and other bleb-related complications in the trabeculectomy cohort of the Collaborative Initial Glauc

94 most commonly with goniotomy, trabeculotomy, trabeculectomy, combined trabeculotomy and trabeculectom

95 the first postoperative day but higher after trabeculectomy compared with EX-PRESS implant on day 7 (

96 identified using glaucoma surgical codes for trabeculectomy, complicated trabeculectomy, glaucoma dra

97 ntify studies representative of the reported trabeculectomy complication rate.

98 Association between the rate of trabeculectomy complications and mitomycin dose used was

99 PURPOSE OF REVIEW: Trabeculectomy continues to be the most effective incisi

100 In the subjects who underwent trabeculectomy, corneal endothelial cell density (ECD) s

101 The tube versus trabeculectomy demonstrated similar intraocular pressure

102 Successful trabeculectomies, determined by Kaplan-Meier analysis, i

103 Eligible patients who refused fellow eye trabeculectomy did not differ significantly in visual fu

104 s of age) underwent an MMC-augmented primary trabeculectomy during the period from April 1996 to Janu

105 bility of bleb-related infections long after trabeculectomy, especially in the presence of identified

106 efractive surprise in cataract surgery after trabeculectomy, especially IOP change and axial length,

107 efractive outcome was -0.36 (more myopic) in trabeculectomy eyes compared with +0.23 (more hyperopic)

108 Mean intraocular pressure (IOP) increased in trabeculectomy eyes from 8.7 +/- 4.2 mm Hg to 10.7 +/- 4

109 underwent needling, respectively, and 50% of trabeculectomy eyes underwent laser suture lysis.

110 57 post-trabeculectomy eyes were included.

111 he time of surgery were more at risk of both trabeculectomy failure and blindness.

112 med to identify risk factors associated with trabeculectomy failure at 8 years.

113 The primary outcome was trabeculectomy failure defined as intraocular pressure (

114 Those at risk of trabeculectomy failure were younger or had uveitic glauc

115 iations between outcome and risk factors for trabeculectomy failure.

116 75 were offered trabeculectomy: five agreed but only one underwent surge

117 o 2 weeks, except in 1 patient, who required trabeculectomy for a refractory intraocular pressure spi

118 and complications of fornix- vs limbal-based trabeculectomy for glaucoma were compared in adult glauc

119 after surgery, whereas the success rates of trabeculectomy for patients who were not treated with TN

120 The success rate of trabeculectomy for patients who were treated with TNF in

121 f Olmsted County, Minnesota, who underwent a trabeculectomy from January 1, 1985, through December 31

122 rgical codes for trabeculectomy, complicated trabeculectomy, glaucoma drainage device, and cycloablat

123 mained popular in the last decade, including trabeculectomy, glaucoma drainage devices, and deep scle

124 was 29.8% in the tube group and 46.9% in the trabeculectomy group (P = .002; hazard ratio = 2.15; 95%

125 the tube group and 39 patients (37%) in the trabeculectomy group (P = .012).

126 rate was 9% in the tube group and 29% in the trabeculectomy group (P = .025).

127 coma was 9% in the tube group and 29% in the trabeculectomy group (P = .025).

128 the tube group and 12.6 +/- 5.9 mm Hg in the trabeculectomy group (P = .12).

129 1.3 in the tube group and 1.2 +/- 1.5 in the trabeculectomy group (P = .23).

130 tube group, and 0%, 9%, 20%, and 47% in the trabeculectomy group (P = .28).

131 ons was 22% in the tube group and 18% in the trabeculectomy group (P = .29).

132 he tube group and 9 phakic eyes (43%) in the trabeculectomy group (P = .43).

133 ient in the tube group and 5 patients in the trabeculectomy group (P = .63).

134 1.3 in the tube group and 1.4 +/- 1.4 in the trabeculectomy group (P = .71).

135 e tube group and 30.5 +/- 20.4 months in the trabeculectomy group (P = .76).

136 the tube group and 14.4 +/- 6.6 mm Hg in the trabeculectomy group (P = .84).

137 he Baerveldt group and 34+/-20 months in the trabeculectomy group (P = 0.053).

138 as 87% in the Baerveldt group and 76% in the trabeculectomy group (P = 0.23).

139 Baerveldt group and 20 patients (29%) in the trabeculectomy group (P = 0.27).

140 ative complications was more frequent in the trabeculectomy group (P<0.001).

141 the tube group and 38 patients (36%) in the trabeculectomy group during 5 years of follow-up (P = .8

142 nts in the tube group and 18 patients in the trabeculectomy group in the TVT Study, and the 5-year cu

143 .1 mmHg (61.3% reduction) at month 24 in the trabeculectomy group.

144 cluding 107 in the tube group and 105 in the trabeculectomy group.

145 Both the EX-PRESS and the trabeculectomy groups were treated intraoperatively with

146 ess rate was 83% and 79% in the EX-PRESS and trabeculectomy groups, respectively (P = 0.563).

147 g and 14.6 +/- 7.1 mm Hg in the EX-PRESS and trabeculectomy groups, respectively (P = 0.927).

148 years were 22.4% and 76.1% in the study and trabeculectomy groups, respectively (P<0.001).

149 p was 27.3 and 25.5 months for the study and trabeculectomy groups, respectively.

150 Ab interno trabeculectomy has a lower success rate than trabeculect

151 aocular pressure lowering effect compared to trabeculectomy has been in the mindset of many glaucoma

152 r glaucoma as well as wound modulation after trabeculectomy has shown great promise.

153 Trabeculectomy, however, is cost-effective at a substant

154 Trabeculectomies in eyes with scarring ranged from 9054

155 Trabeculectomies in eyes without previous scarring decre

156 erformed nine trabectome-mediated ab interno trabeculectomies in pig eyes (n = 63).

157 veness of intraocular pressure lowering with trabeculectomy in decreasing the risk of future disc hem

158 mparable to primary AGV implantation, and to trabeculectomy in eyes with a previously implanted glauc

159 reasonable IOP targets after a first failed trabeculectomy in open-angle glaucoma patients.

160 (thermal sclerostomy) in the 1950s and then trabeculectomy in the 1970s.

161 plications in the 300 patients randomized to trabeculectomy in the Collaborative Initial Glaucoma Tre

162 ared between groups that received or refused trabeculectomy in their fellow eye.

163 Performing cataract surgery after trabeculectomy increases the odds of filtration failure

164 There was no difference in pre-trabeculectomy IOP between DSAEK vs PK group (35.5 +/- 1

165 Trabeculectomy is an effective surgical procedure for th

166 ulectomy or combined phacoemulsification and trabeculectomy is associated with similar complete succe

167 Adjunctive subconjunctival bevacizumab with trabeculectomy is effective in controlling the IOP profi

168 Trabeculectomy is the surgical standard of care for pati

169 Traditionally, trabeculectomy is usually recommended to patients as the

170 In 334 patients, 460 eyes underwent trabeculectomy (mean [SD; range] follow-up, 7.7 [5.7; 0-

171 At 12 months after trabeculectomy, mean IOP in the DSAEK group was lower co

172 The potential efficacy of trabeculectomy must be weighed against the long-term ris

173 = 9), glaucoma drainage device (n = 6), and trabeculectomy (n = 1).

174 t-penetrating keratoplasty (n = 2), and post-trabeculectomy (n = 2).

175 tion with IOL implant at least 3 months post-trabeculectomy (n = 77) with eyes with either medically

176 was negatively correlated with low IOP after trabeculectomy (odds ratio [OR], 0.33; 95% confidence in

177 2 years (95% CI, 0.3-9.9 years), whereas the trabeculectomies of patients who were not treated with T

178 The trabeculectomies of patients who were treated with TNF i

179 cipants who were randomized to and underwent trabeculectomy on their study eye and had a fellow eye t

180 who were randomized to and underwent initial trabeculectomy on their study eye, and whose fellow eye

181 laucoma drainage device (GDD) and those with trabeculectomy only was 25% and 59%, respectively.

182 Patients with uncontrolled IOP requiring trabeculectomy or aqueous drainage device were enrolled.

183 Use of the CM implant at the time of trabeculectomy or combined phacoemulsification and trabe

184 essure (IOP)-lowering efficacy and safety of trabeculectomy or combined phacoemulsification and trabe

185 oring the use of anti-VEGF agents at time of trabeculectomy or in bleb revision procedures suggest a

186 th preexisting glaucoma surgical procedures (trabeculectomy or tube shunts), special attention to tec

187 n was correlated with high vs. low IOP after trabeculectomy (OR, 5.32; 95% CI, 1.53-18.52).

188 ifference in the need for intervention after trabeculectomy, or incidence of other complications.

189 ith ischemic nonfunctioning blebs and patent trabeculectomy ostia.

190 This survey shows that good trabeculectomy outcomes with low rates of surgical compl

191 PRESS implant (P = 0.285) and 3 months after trabeculectomy (P = 0.255).

192 The mean number of trabeculectomies per eye was significantly higher in car

193 Of 3659 total trabeculectomies performed by 5 surgeons between 1990 an

194 Glaucoma patients at a VAH with primary trabeculectomy performed by residents under attending su

195 owever, the visual outcomes of patients with trabeculectomy performed by residents were worse in the

196 y augmented with Ologen implant (OLO) versus trabeculectomy plus mitomycin-C (MMC) show contradictory

197 e the methodology of the Primary Tube Versus Trabeculectomy (PTVT) Study.

198 The rate of trabeculectomy-related complications does not appear to

199 Trabeculectomy remains the most efficient method of lowe

200 Combining cataract surgery with a trabeculectomy remains the preferred option.

201 Low IOP after trabeculectomy, reoperation, vision loss, and surgical f

202 Participants who underwent trabeculectomy reported a higher frequency of any Local

203 anti-VEGF agents for wound modulation after trabeculectomy reveal promising results.

204 interval between the first and the same-site trabeculectomy revision of <3 years, worse baseline visu

205 significant medication reduction, same-site trabeculectomy revision with MMC should be considered as

206 >/=40 years of age at the time of same-site trabeculectomy revision, were included.

207 Trabeculectomy seems to be the most effective surgical p

208 Cataract surgery alone or combined with trabeculectomy should be considered in the treatment of

209 A prior glaucoma shunt or trabeculectomy significantly increased the risk of DSEK

210 During 2009, 439 trabeculectomy sites of 347 patients were quantitatively

211 The results show that trabeculectomy slows the rate of perimetric decay and pr

212 Findings of the Tube Versus Trabeculectomy study resulted in an expanded use of tube

213 There is an increasing need to prolong trabeculectomy success rates with minimally invasive pro

214 trabeculectomies and can potentially prolong trabeculectomy success rates.

215 1 patients (80 procedures) who had undergone trabeculectomy surgery after failed medical management a

216 ncontrolled glaucoma underwent microstent or trabeculectomy surgery from January 1, 2011 through July

217 traocular pressure (IOP) predicts outcome of trabeculectomy surgery in patients with primary open ang

218 re-operative IOP does not predict success of trabeculectomy surgery in POAG patients during the first

219 Trabeculectomy surgery is therefore a long-term solution

220 s undertaken to determine the performance of trabeculectomy surgery over a 20-year period and examine

221 may have an advantage in terms of success of trabeculectomy surgery over PK.

222 Trabeculectomy surgery performed by 2 experienced glauco

223 Similar efficacy of trabeculectomy surgery with respect to bleb failure or I

224 iveness between fornix-based vs limbal-based trabeculectomy surgery, although with a high level of un

225 The primary outcome was success of trabeculectomy surgery, with failure defined as intraocu

226 f mitomycin C (MMC) to prevent scarring with trabeculectomy surgery.

227 rnix- and limbal-based conjunctival flaps in trabeculectomy surgery.

228 This study indicates that trabeculectomy survival at 20 years may be approximately

229 ly compared nonpenetrating surgery (NPS) and trabeculectomy (TE).

230 A contemporary pediatric trabeculectomy technique augmented with MMC is an effect

231 postoperative complications was higher after trabeculectomy than after EX-PRESS implantation (P = 0.0

232 wer rate of cataract surgery performed after trabeculectomy than those in the attending group.

233 systemic TNF inhibitors at the time of their trabeculectomy to control their uveitis, arthritis, or b

234 Patients who underwent trabeculectomy (Trab) with mitomycin-C (74 eyes of 64 pa

235 The Tube vs Trabeculectomy Trial (TVT) found that the 350-mm2 Baerve

236 , trabeculectomy, combined trabeculotomy and trabeculectomy, tube shunt surgery, cyclodestruction, an

237 PURPOSE OF REVIEW: The Tube Versus Trabeculectomy (TVT) Study is a multicenter randomized c

238 The Tube Versus Trabeculectomy (TVT) Study is a multicenter randomized c

239 ty-of-life (QoL) outcomes in the Tube Versus Trabeculectomy (TVT) Study.

240 plopia was more commonly seen after GDD than trabeculectomy, typically a noncomitant restrictive hype

241 Trabeculectomy use continued its long-term downward tren

242 t-effectiveness ratio was $8289 per QALY for trabeculectomy vs medical treatment, $13 896 per QALY fo

243 sertion, and $2203 (95% CI, $2121-$2261) for trabeculectomy vs tube insertion.

244 HR of failure of the microstent relative to trabeculectomy was 1.2 (95% confidence interval [CI], 0.

245 The mean (SD) time of LGP after trabeculectomy was 35.7 (32.3) months, and the mean (SD)

246 Prior trabeculectomy was associated with a higher rate of visi

247 roup of VAH patients with resident-performed trabeculectomy was case-matched to private patients with

248 (control group), in which only a successful trabeculectomy was conducted.

249 The surgical success of the trabeculectomy was expressed as IOP < 17 mmHg.

250 Corneal graft failure arising after trabeculectomy was seen in 10.0% of DSAEK cases and in 1

251 ons of eyes that required intervention after trabeculectomy were comparable between the 2 groups (DSA

252 ccess rates of limbus-based and fornix-based trabeculectomy were not statistically different for any

253 t had failed or were at high risk of failing trabeculectomy were randomized to receive an Ahmed impla

254 Control patients without low IOP after trabeculectomy were randomly selected at a 1:2 case-to-c

255 s (study group) in which, after a successful trabeculectomy with 5-Fluorouracil, phacoemulsification

256 ficacy as well as safety profile compared to trabeculectomy with antimetabolites.

257 safety and efficacy of tube-shunt surgery to trabeculectomy with mitomycin (MMC) in eyes with previou

258 In order to lower IOP, trabeculectomy with mitomycin C (0.2 mg/cc) was performe

259 nt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (0.4 mg/ml for 2 minutes

260 rveldt glaucoma implant) and 105 patients to trabeculectomy with mitomycin C (0.4 mg/mL for 4 minutes

261 nt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C ([MMC]; 0.4 mg/mL for 4

262 nt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC 0.4 mg/mL for 4 min

263 ithin an institutional setting who underwent trabeculectomy with mitomycin C (MMC) for uncontrolled e

264 safety and efficacy of tube-shunt surgery to trabeculectomy with mitomycin C (MMC) in eyes with previ

265 Trabeculectomy with mitomycin C (MMC) is a major treatme

266 eoperation for glaucoma was higher following trabeculectomy with mitomycin C than tube shunt surgery

267 o overfiltration following glaucoma surgery (trabeculectomy with mitomycin C) were included in this i

268 hat the 350-mm2 Baerveldt implant (tube) and trabeculectomy with mitomycin may be similarly effective

269 m clinical data on the cost-effectiveness of trabeculectomy with mitomycin vs tube insertion.

270 ulectomy or combined phacoemulsification and trabeculectomy with mitomycin-C (MMC) vs. Collagen Matri

271 ction (2.5 mg/0.1 mL), and 18 eyes underwent trabeculectomy with MMC (0.02% for 3 minutes).

272 cations were observed in patients undergoing trabeculectomy with MMC and in those undergoing Baerveld

273 he rate of vision loss was present following trabeculectomy with MMC and tube-shunt surgery after 3 y

274 Tube-shunt surgery and trabeculectomy with MMC are both viable surgical options

275 postoperative complications was higher after trabeculectomy with MMC compared with tube-shunt surgery

276 urgery had a higher success rate compared to trabeculectomy with MMC during 5 years of follow-up in t

277 d with use of more glaucoma medications than trabeculectomy with MMC during the first 2 years of the

278 eater use of adjunctive-medical therapy than trabeculectomy with MMC during the first 2 years of the

279 shunt surgery had a higher success rate than trabeculectomy with MMC during the first 3 years of foll

280 Trabeculectomy with MMC had higher rates of surgical fai

281 orty glaucoma patients (40 eyes) assigned to trabeculectomy with MMC or Ologen.

282 Trabeculectomy with MMC produced greater intraocular pre

283 RECENT FINDINGS: Both tube-shunt surgery and trabeculectomy with MMC produced intraocular pressure (I

284 Early complications were more frequent after trabeculectomy with MMC relative to tube-shunt surgery,

285 oma surgery was needed more frequently after trabeculectomy with MMC than tube shunt placement.

286 operative complications was higher following trabeculectomy with MMC than tube shunt surgery.

287 tandalone ab interno microstent with MMC and trabeculectomy with MMC.

288 t implantation with mitomycin C (MMC) versus trabeculectomy with MMC.

289 nt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with MMC.

290 y, -0.42; 95% CI, -0.85 to 0.01; P = 0.053), trabeculectomy with previous surgery (elasticity, -0.28;

291 Eighteen eyes underwent trabeculectomy with subconjunctival bevacizumab injectio

292 the attention has been focused on comparing trabeculectomy with the Baerveldt implant (Advanced Medi

293 to two novel surgical approaches: ab interno trabeculectomy with the Trabectome and implantation of t

294 Patients undergoing trabeculectomy (with or without cataract surgery) or tub

295 eyes of 293 patients (185 microstent and 169 trabeculectomy) with no prior incisional surgery.

296 Trabeculectomy within 6 to 24 months after phacoemulsifi

297 00 eyes of 100 patients previously undergone trabeculectomy without antimetabolites, divided into two

298 dy period, 797 eyes of 634 persons underwent trabeculectomy without concurrent surgery.

299 nce interval [CI], -1.31 to 0.77; P = 0.61), trabeculectomy without previous surgery (elasticity, -0.

300 uce intraocular pressure (IOP) comparable to trabeculectomy without the risk of serious bleb-related